$TCRT
Alaunos Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518159174 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $146.0K $1.597M
YoY Change -100.0% -90.86% -18.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.890M $6.160M $3.600M
YoY Change 29.37% 71.11% -5.51%
% of Gross Profit
Research & Development $7.489M $10.18M $11.97M
YoY Change -30.86% -14.91% 17.34%
% of Gross Profit
Depreciation & Amortization $140.0K $117.0K $80.00K
YoY Change 55.56% 46.25% 14.29%
% of Gross Profit
Operating Expenses $12.38M $16.34M $11.97M
YoY Change 14.28% 36.56% 17.34%
Operating Profit -$12.38M -$16.20M -$13.97M
YoY Change -4.89% 15.98% 15.99%
Interest Expense $180.0K $30.00K -$1.560M
YoY Change 157.14% -101.92%
% of Operating Profit
Other Income/Expense, Net $164.0K $148.0K $38.00K
YoY Change 90.7% 289.47% 80.95%
Pretax Income -$12.03M -$16.02M -$15.49M
YoY Change -6.45% 3.42% 28.87%
Income Tax
% Of Pretax Income
Net Earnings -$17.49M -$21.14M -$19.66M
YoY Change -1.32% 7.54% 63.56%
Net Earnings / Revenue -14479.45% -1230.93%
Basic Earnings Per Share -$0.12 -$0.15
Diluted Earnings Per Share -$0.12 -$0.15 -$0.15
COMMON SHARES
Basic Shares Outstanding 142.4M shares 142.4M shares 132.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.40M $51.10M $66.40M
YoY Change -58.44% -23.04% -46.79%
Cash & Equivalents $40.40M $51.11M $66.45M
Short-Term Investments
Other Short-Term Assets $11.90M $21.00M $26.20M
YoY Change -57.35% -19.85% 80.69%
Inventory
Prepaid Expenses
Receivables $700.0K $0.00 $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $52.99M $72.12M $92.75M
YoY Change -57.65% -22.25% -33.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.332M $1.244M $1.124M
YoY Change 25.42% 10.68% 68.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.93M $13.97M $492.0K
YoY Change 4348.28% 2740.24% -1.2%
Total Long-Term Assets $23.39M $15.35M $1.744M
YoY Change 1289.78% 779.93% 34.88%
TOTAL ASSETS
Total Short-Term Assets $52.99M $72.12M $92.75M
Total Long-Term Assets $23.39M $15.35M $1.744M
Total Assets $76.38M $87.46M $94.49M
YoY Change -39.77% -7.44% -33.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $588.0K $606.0K $226.0K
YoY Change 625.93% 168.14% -88.16%
Accrued Expenses $8.663M $8.878M $10.69M
YoY Change -7.39% -16.93% 24.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.314M $10.06M $17.46M
YoY Change -41.74% -42.38% 1.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $51.90M $51.50M $42.50M
YoY Change 26.89% 21.18% -8.8%
Total Long-Term Liabilities $51.90M $51.50M $42.50M
YoY Change 26.89% 21.18% -8.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.314M $10.06M $17.46M
Total Long-Term Liabilities $51.90M $51.50M $42.50M
Total Liabilities $61.19M $61.57M $59.96M
YoY Change 7.63% 2.7% -6.13%
SHAREHOLDERS EQUITY
Retained Earnings -$748.6M -$736.6M -$673.6M
YoY Change 9.05% 9.35% 33.46%
Common Stock $609.4M $613.4M $578.7M
YoY Change -2.06% 6.0% -0.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$139.2M -$123.1M -$94.90M
YoY Change
Total Liabilities & Shareholders Equity $76.38M $87.46M $94.49M
YoY Change -39.77% -7.44% -33.31%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$17.49M -$21.14M -$19.66M
YoY Change -1.32% 7.54% 63.56%
Depreciation, Depletion And Amortization $140.0K $117.0K $80.00K
YoY Change 55.56% 46.25% 14.29%
Cash From Operating Activities -$10.17M -$18.96M -$14.28M
YoY Change -34.47% 32.75% -11.19%
INVESTING ACTIVITIES
Capital Expenditures $230.0K $150.0K $358.0K
YoY Change 666.67% -58.1% 128.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$230.0K -$150.0K -$360.0K
YoY Change 666.67% -58.33% 125.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $731.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -310.0K -731.0K 30.00K
YoY Change -100.67% -2536.67% -91.89%
NET CHANGE
Cash From Operating Activities -10.17M -18.96M -14.28M
Cash From Investing Activities -230.0K -150.0K -360.0K
Cash From Financing Activities -310.0K -731.0K 30.00K
Net Change In Cash -10.71M -19.84M -14.61M
YoY Change -134.83% 35.78% -7.94%
FREE CASH FLOW
Cash From Operating Activities -$10.17M -$18.96M -$14.28M
Capital Expenditures $230.0K $150.0K $358.0K
Free Cash Flow -$10.40M -$19.11M -$14.64M
YoY Change -33.12% 30.53% -9.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 ziop Sharebased Compensation Arrangement By Sharebased Payment Award Option Having Contractual Life Extended
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionHavingContractualLifeExtended
751667 shares
CY2018Q1 ziop Sharebased Compensation Arrangement By Sharebased Payment Award Option Having Contractual Life Extended
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionHavingContractualLifeExtended
117500 shares
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
142398936 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66447000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66835000
CY2017Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
388000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142398936 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
403962 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142398936 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2951502 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.83
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3822968 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.08
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-736593000
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Liabilities
Liabilities
61571000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87461000
CY2018Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2469000
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
476000
CY2018Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
105000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
606000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-123149000
CY2018Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2469000
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
49037000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
142000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
613302000
CY2018Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
476000
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10062000
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
102000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8878000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
72115000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1244000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1019000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51108000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51497000
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
389000
CY2018Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2018Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
18000
CY2018Q1 us-gaap Assets
Assets
87461000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13974000
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20989000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1020000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81441000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142658037 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142658037 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2925502 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3852135 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-712442000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Liabilities
Liabilities
58420000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105606000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2424000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
142000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4417000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2424000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35139000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
615493000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1152000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70946000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71335000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
19000
CY2017Q4 us-gaap Assets
Assets
105606000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20856000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
141000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9909000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
90783000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1211000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13484000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19818000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M29D
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25727662 shares
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14277000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8090 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8031 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0204 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.48
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130696400 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0223 pure
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
117000 shares
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
358000
CY2017Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1560000
CY2017Q1 us-gaap Contracts Revenue
ContractsRevenue
1597000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13965000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-15487000
CY2017Q1 us-gaap Interest Paid
InterestPaid
0
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19658000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2426000
CY2017Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
46000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
70000
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-31000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-358000
CY2017Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4171000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2024000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14606000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
79000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1597000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3595000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1577000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29000
CY2017Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15562000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
172000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11967000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40507258 shares
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18957000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8110 pure
CY2018Q1 dei Trading Symbol
TradingSymbol
ZIOP
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.93
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.27
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8075 pure
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0256 pure
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M9D
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
36667 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.00
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140853120 shares
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7500 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0274 pure
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7500 shares
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
150000
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
490000
CY2018Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
28000
CY2018Q1 us-gaap Contracts Revenue
ContractsRevenue
146000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16196000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-16020000
CY2018Q1 us-gaap Interest Paid
InterestPaid
0
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-8131000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3659000
CY2018Q1 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
731000
CY2018Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
148000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21140000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1172000
CY2018Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3811000
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-37000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-150000
CY2018Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5120000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3659000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19838000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
117000
CY2018Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
5120000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-146000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6159000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1030000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-731000
CY2018Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
16342000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
176000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10183000
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0
CY2018Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
731000
CY2018Q1 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
73000
CY2018Q1 ziop Additional Share Based Compensation Expense
AdditionalShareBasedCompensationExpense
481000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
40000

Files In Submission

Name View Source Status
0001193125-18-159174-index-headers.html Edgar Link pending
0001193125-18-159174-index.html Edgar Link pending
0001193125-18-159174.txt Edgar Link pending
0001193125-18-159174-xbrl.zip Edgar Link pending
d569386d10q.htm Edgar Link pending
d569386dex311.htm Edgar Link pending
d569386dex312.htm Edgar Link pending
d569386dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g56938637a.jpg Edgar Link pending
g56938638a.jpg Edgar Link pending
g56938643a.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20180331.xml Edgar Link completed
ziop-20180331.xsd Edgar Link pending
ziop-20180331_cal.xml Edgar Link unprocessable
ziop-20180331_def.xml Edgar Link unprocessable
ziop-20180331_lab.xml Edgar Link unprocessable
ziop-20180331_pre.xml Edgar Link unprocessable